ThreeD Capital Inc. Announces Unaudited April 30, 2024 Net Asset Value Per Share – $0.75
TORONTO, May 06, 2024 (GLOBE NEWSWIRE) — ThreeD Capital Inc. (“ThreeD” or the “Company”) (CSE:IDK / OTCQX:IDKFF) a Canadian-based venture […]
Array and DNV Release Report on Solar Tracker Wind Stow Strategies’ Energy Impact
ALBUQUERQUE, N.M., May 06, 2024 (GLOBE NEWSWIRE) — Array Technologies (NASDAQ: ARRY), a leading provider of solar tracking solutions, confirmed […]
T2 Biosystems Announces First Quarter 2024 Financial Results
LEXINGTON, Mass., May 06, 2024 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of […]
T2 Biosystems Announces Commercial Expansion Through Middle East Distributor
Filed Pursuant to Rule 433 Issuer Free Writing Prospectus dated May 6, 2024 Relating to Preliminary Prospectus dated May 6, […]
Mueller Water Products Reports 2024 Second Quarter Results
Increased Net Sales 6.2 percent to $353.4 Million Reported Net Income per Diluted Share of $0.28 Achieved Record Adjusted Net […]
Pineapple Energy to Release First Quarter 2024 Results, Host Conference Call on May 10
MINNETONKA, Minn., May 06, 2024 (GLOBE NEWSWIRE) — Pineapple Energy Inc. (NASDAQ: PEGY), a leading provider of sustainable solar energy […]
The Metals Company Announces First Quarter 2024 Corporate Update Conference Call for Monday, May 13, 2024
NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) — The Metals Company (Nasdaq: TMC) (“TMC” or “the Company”), an explorer of […]
Safe Harbor Financial to Report First Quarter 2024 Financial Results on Monday, May 13, 2024
GOLDEN, Colo., May 06, 2024 (GLOBE NEWSWIRE) — SHF Holdings, Inc., d/b/a/ Safe Harbor Financial (“Safe Harbor” or the “Company”) […]
Immuneering Recognizes Melanoma Awareness Month
– Two clinical stage product candidates in development for the treatment of melanoma – – RAS mutant melanoma represents one […]
Day One Reports First Quarter 2024 Financial Results and Corporate Progress
OJEMDA™ (tovorafenib) launch underway following U.S. FDA accelerated approval for relapsed or refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG) First prescriptions […]
